Ketamine FAQ
Everything You Need to Know as You Begin Your Journey With Us.
Frequently Asked Questions About Ketamine Therapy
Ketamine has been used medically since the 1960s and is included on the World Health Organization List of Essential Medicines. Esketamine, a derivative of ketamine, is also FDA-approved for treatment-resistant depression alongside an oral antidepressant through a program overseen by the U.S. Food and Drug Administration.
Explore the Integration Process
- Treatment-resistant depression
- Chronic anxiety
- Trauma-related symptoms or PTSD
- Burnout or persistent emotional distress
- Substance Use Disorder (SUD) and Alcoholism (stable and in recovery)
- Other symptoms, including Stable Bipolar, OCD, and Grief Reaction.
Never stop or adjust prescribed medications without consulting a healthcare provider. Specific medications will be discussed during intake.
- Confusion, disorientation, or anxiety.
- Altered perception or dissociation.
- Dizziness, sedation, or mild tremor.
- Headache or blurred vision.
- Nausea or vomiting.
- Temporary increases in blood pressure/heart rate.
- Long-term (rare): Cystitis or elevations in liver enzymes.
Ketamine therapy may be reimbursed by some insurance plans, while others do not provide coverage. Payment for treatment is accepted upfront by credit card or check. A superbill can be provided, and Robin can also submit it to your insurance carrier on your behalf for potential reimbursement. Reimbursement is never guaranteed. Some individuals may also qualify for financing options through the Advance Care Card.
Evidence, Ethics, and Your Care
Research on ketamine and depression:
A 2023 systematic review and meta-analysis published in eClinicalMedicine evaluated randomized controlled trials examining ketamine formulations for major depressive disorder. The analysis included 49 studies involving 3,299 participants. Ketamine was associated with reductions in depressive symptom severity compared with control conditions. Dose was identified as a relevant factor, with higher doses generally associated with greater reductions in symptom severity. Research findings are based on population-level data and do not predict individual outcomes.
Citation: Nikolin, S., et al. (2023). Ketamine for the treatment of major depression: A systematic review and meta-analysis. eClinicalMedicine, 62.
Clinical and Ethical Context:
Ketamine research continues to evolve. Large-scale, long-term studies are ongoing, particularly regarding optimal dosing, durability of effects, and predictors of response. This evolving evidence underscores the importance of medical supervision, psychological support, and informed consent.
Good Faith Estimate
Under the No Surprises Act, clients have the right to receive a Good Faith Estimate outlining expected costs. If billed charges exceed the estimate by $400 or more, there is a right to dispute the bill.
